Vogenx, Inc. (NASDAQ:VOGX) reported its third-quarter 2026 financial results and provided an update on its clinical pipeline, financing and management team. The Raleigh, North Carolina-based clinical-stage biopharmaceutical company said its cash, cash equivalents and marketable securities totalled $82.1 million as of September 30, 2026.
#EMERGE study evaluates mizagliflozin in PBH
Vogenx initiated the EMERGE study (NCT07760961) in October 2026. The Phase 2b trial is randomised, placebo-controlled, double-blind and parallel-group, and is evaluating mizagliflozin 5 mg and 10 mg administered for 28 days in approximately 36 adults with post-bariatric hypoglycaemia, or PBH.
The study is being conducted at multiple centres in the United States. Vogenx said topline results are expected in the second half of 2027. The company also plans to begin a Phase 2 study of mizagliflozin in gastroparesis in the first half of 2027.
Vogenx identifies the timing, enrolment and results of EMERGE, along with its clinical development plans, as forward-looking matters subject to risks and uncertainties. Those risks include clinical-trial execution and results, the possibility that earlier studies may not predict later studies, regulatory review, competition and reliance on third parties such as clinical research organisations and trial sites.
#IPO increases reported cash position
Vogenx completed a $93.4 million IPO in August 2026. The offering involved 7,187,500 shares of common stock sold at a public offering price of $13.00 per share, including 937,500 additional shares issued after the underwriter exercised its option in full.
After underwriting discounts, commissions and offering expenses payable by the company, Vogenx received net proceeds of approximately $84.4 million. The company reported cash, cash equivalents and marketable securities of $82.1 million as of September 30, 2026, compared with $601 thousand as of December 31, 2025, and attributed the increase to the IPO proceeds.
#Operating expenses and quarterly loss
Research and development expenses were $1.1 million for the three months ended September 30, 2026, compared with $125 thousand for the same period in 2025. Vogenx attributed the increase primarily to $714 thousand in direct programme expenses for the PBH EMERGE Phase 2b study and expanded department headcount.
General and administrative expenses were $704 thousand for the three months ended September 30, 2026, versus $178 thousand for the three months ended September 30, 2025. The company said the change reflected $237 thousand in personnel costs and $214 thousand in incremental public company operational expenses.
Vogenx recorded a net loss of $4.9 million, or $(0.47) per basic and diluted share, for the three months ended September 30, 2026. For the same period in 2025, it reported a net loss of $284 thousand, or $(0.05) per basic and diluted share. The 2026 quarterly loss included operating expenses of $1.8 million and a $3.4 million change in warrant liability, partly offset by $0.3 million of interest income.
#Board and management changes
In September 2026, Ken Toombs joined Vogenx's board as an independent director and became chair of the audit committee.
Rich Gorman joined the management team as chief commercial officer in October 2026. His resignation as an independent board member took effect on October 12, 2026. In his management role, Gorman is responsible for commercial operations, corporate strategy and business development.
#Company pipeline and stated risks
Vogenx is developing mizagliflozin for post-bariatric hypoglycaemia, gastroparesis and GIP-dependent Cushing's Syndrome. The company describes itself as focused on discovering and developing therapeutics for serious metabolic and gastrointestinal diseases with high unmet medical need.
Vogenx said its forward-looking statements are also subject to risks involving its licence from Kissei Pharmaceutical Co., Ltd., the need for additional capital, its limited operating history, dependence on a small number of key personnel and material weaknesses in internal control over financial reporting. It stated that these and other factors could cause actual results to differ materially from current expectations.
#Key Takeaways
- Vogenx reported $82.1 million in cash, cash equivalents and marketable securities as of September 30, 2026.
- The company initiated the EMERGE Phase 2b study of mizagliflozin in approximately 36 adults with post-bariatric hypoglycaemia.
- Vogenx reported a third-quarter net loss of $4.9 million, or $(0.47) per basic and diluted share.
- The August 2026 IPO involved 7,187,500 shares at a public offering price of $13.00 per share and generated approximately $84.4 million in net proceeds.
- Vogenx plans to initiate a Phase 2 gastroparesis study in the first half of 2027, while topline EMERGE results are expected in the second half of 2027.
Original source: Read original article